. "9. Findings, Conclusions, and Recommendations." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
TABLE 9.4 The Effect of Resource Constraints on the Ranking of Various Vaccine Candidates
Rank Based on Annualized Present Value of Potential Health Benefits Adjusted for Opportunity Costsa
b– denotes not affordable at indicated willingness to pay.
equivalent to potential health benefits. In this case the principle of dominance applies: vaccines yielding greater potential benefits and lower expenditures are preferred. Procedures are discussed in Chapter 3. However, because the expenditures do not reflect overall net costs, the committee believes that initial rankings of candidates should be based on their potential health benefits.
Disease Burden Assumptions
A major factor in determining the ultimate ranking of a vaccine candidate is the total disease burden value (TDBV) used as the starting point in the calculations of potential benefit. The central analysis rankings reflect the committee’s best efforts, within its resources and the reliability and quantity of available data, to generate disease
